Banister
发表于 2025-3-26 21:36:41
http://reply.papertrans.cn/63/6288/628714/628714_31.png
担忧
发表于 2025-3-27 01:14:15
Targeting DNA Repair,anding of the molecular mechanisms through which the DNA damage response (DDR) operates, in combination with the elucidation of the genetic interactions between DDR pathways and other cell pathways, will provide therapeutic opportunities for the personalized medicine of cancer.
合并
发表于 2025-3-27 06:44:12
Book 2018 rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities..
有恶臭
发表于 2025-3-27 12:11:17
0171-2004 f issues including pharmacodynamic and pharmacokinetic mecha.A major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarker
Dawdle
发表于 2025-3-27 15:36:29
Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm,asons and inefficient and heterogeneous tumor drug distribution, related to a deficient vascularization and high interstitial pressure. Finally, resistance can be related to the activation of anti-apoptotic and cell survival pathways by cancer cells and often enhanced by tumor microenvironment.
GROSS
发表于 2025-3-27 18:30:23
Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia,been identified, ranging from BCR-ABL1 kinase domain mutations to lack of adherence to therapy. In this review, we briefly summarize the clinical efficacy of approved TKIs and describe the main mechanisms of TKI resistance.
荧光
发表于 2025-3-28 00:28:17
http://reply.papertrans.cn/63/6288/628714/628714_37.png
改良
发表于 2025-3-28 05:08:08
http://reply.papertrans.cn/63/6288/628714/628714_38.png
habile
发表于 2025-3-28 09:57:40
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer,transition). These basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. Novel-generation molecules include osimertinib, for EGFR-T790M-positive patients, and new ALK-TKIs. Nevertheless, the possible concomitant presence of multiple resi
画布
发表于 2025-3-28 13:30:54
http://reply.papertrans.cn/63/6288/628714/628714_40.png